Organisation: Massachusetts Institute of Technology

Via Licensing Alliance’s Heath Hoglund takes the top spot in our annual ranking of the patent market’s most innovative and influential deal makers and decision takers

14 March 2024

The speedy agreement prevents litigation between the two parties, but other Cas9 disputes may be on the cards

14 December 2023

Friday’s green light from the FDA is watershed for IP strategy in the field

11 December 2023

Green light for first ever Cas9 therapy ushers in next phase of licensing and litigation efforts.

17 November 2023

IAM speaks exclusively to Christopher Arnot about the crowded CRISPR IP landscape

25 August 2023

Nanoco Technology counts IP as a “key strength” with manufacturing royalties and patent licence fees as a small but growing part of its revenue base

16 January 2023

EPO Opposition Division upholds another key Doudna patent, but several gene-editing appeals are still in play

26 May 2022

The long read: Womble Bond Dickinson’s Ben Bourke takes a deep dive into how life science companies have handled their IP portfolios over the covid-19 pandemic – in particular Moderna Therapeutics’ pledge not to enforce patents relating to its vaccine – and examines how such adjustments can prepare the ground for future inventions

07 April 2021

A strategy for protecting and exploiting data is now a must for entities involved in healthcare research

25 February 2021

There are circumstances under which the model can definitely work, but these may not apply to all industries and might mean licensors having to modify their financial expectations

15 August 2019